Stay updated on Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial
Sign up to get notified when there's something new on the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page.

Latest updates to the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check35 days agoNo Change Detected
- Check43 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference5%
- Check50 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check64 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.3%
- Check71 days agoChange DetectedThe type of intervention has been updated to a verified status by Harbour BioMed, with the last known status indicating it is not yet recruiting, reflecting a revision from v2.13.3 to v2.14.0.SummaryDifference3%
- Check100 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
Stay in the know with updates to Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of HBM4003 + Toripalimab in Antitumor Clinical Trial page.